The prevalence, impact and economic implications of atrial fibrillation in stroke: What progress has been made?

Neuroepidemiology

Volumn 40, Issue 4, 2013, Pages 229-239

  Andrew, Nadine E ^a   Thrift, Amanda G ^a,b   Cadilhac, Dominique A ^a,b,c  

^a MONASH UNIVERSITY   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Atrial fibrillation; Economic evaluation; Prevalence; Risk; Stroke

Indexed keywords

ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; ECONOMIC ASPECT; ETHNIC GROUP; GROUPS BY AGE; HEALTH CARE COST; HUMAN; INCIDENCE; OUTCOME ASSESSMENT; PREVALENCE; PRIMARY PREVENTION; REVIEW; RISK FACTOR;

EID: 84873054619     PISSN: 02515350     EISSN: 14230208     Source Type: Journal    
DOI: 10.1159/000343667     Document Type: Review

References (59)

1. Arboix A, Garcia-Eroles L, Massons JB, Oliveres M, Pujades R, Targa C: Atrial fibrillation and stroke: clinical presentation of cardioembolic versus atherothrombotic infarction. Int J Cardiol 2000; 73: 33-42.
2. Paciaroni M, Agnelli G, Caso V, Venti M, Milia P, Silvestrelli G, Parnetti L, Biagini S: Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. J Thromb Haemost 2005; 3: 1218-1223.
3. Lamassa M, Di Carlo A, Pracucci G, Basile AM, Trefoloni G, Vanni P, Spolveri S, Baruffi MC, Landini G, Ghetti A, Wolfe CD, Inzitari D: Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001; 32: 392-398.
4. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB: Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27: 1760-1764.
5. Sandhu RK, Bakal JA, Ezekowitz JA, McAlister FA: The epidemiology of atrial fibrillation in adults depends on locale of diagnosis. Am Heart J 2011; 161: 986-992.e1.
6. Biblo L, Yuan Z, Quan K, Mackall J, Rimm A: Risk of stroke in patients with atrial flutter. Am J Cardiol 2001; 87: 346-349.
7. Hobbs FDR, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, Raftery J, Davies M, Lip G: A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005; 9:iii-iv, ix-x, 1-74.
8. Wolf PA, Kannel WB, McGee DL, Meeks SL, Bharucha NE, McNamara PM: Duration of atrial fibrillation and imminence of stroke: The Framingham study. Stroke 1983; 14: 664-667.
9. Savelieva I, Camm AJ: Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 2000; 4: 369-382.
10. Flaker GC, Belew K, Beckman K, Vidaillet H, Kron J, Safford R, Mickel M, Barrell P: Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149: 657-663.
11. Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R: Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke 2004; 35: 1647-1651.
12. Bansil S, Karim H: Detection of atrial fibrillation in patients with acute stroke. J Stroke Cerebrovasc Dis 2004; 13: 12-15.
13. Parkash R, Wee V, Gardner MJ, Cox JL, Thompson K, Brownell B, Anderson DR: The impact of warfarin use on clinical outcomes in atrial fibrillation: A populationbased study. Can J Cardiol 2007; 23: 457-461.
14. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
15. DeWilde S, Carey IM, Emmas C, Richards N, Cook DG: Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 2006; 92: 1064-1070.
16. Benjamin EJ, Chen P-S, Bild DE, Mascette AM, Albert CM, Alonso A, Calkins H, Connolly SJ, Curtis AB, Darbar D, Ellinor PT, Go AS, Goldschlager NF, Heckbert SR, Jalife J, Kerr CR, Levy D, Lloyd-Jones DM, Massie BM, Nattel S, Olgin JE, Packer DL, Po SS, Tsang TSM, Van Wagoner DR, Waldo AL, Wyse DG: Prevention of atrial fibrillation: report from a National Heart, Lung, and Blood Institute workshop. Circulation 2009; 119: 606-618.
17. Kristman V, Manno M, Cote P: Loss to follow-up in cohort studies: how much is too much? Eur J Epidemiol 2004; 18: 751-760.
18. Sudlow CL, Warlow CP: Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration. Stroke 1997; 28: 491-499.
19. von Elm E, Altman D, Egger M, Pocock S, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007; 4:e296.
20. Ruo B, Capra AM, Jensvold NG, Go AS: Racial variation in the prevalence of atrial fibrillation among patients with heart failure: The Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. J Am Coll Cardiol 2004; 43: 429-435.
21. Rietbrock S, Heeley E, Plumb J, van Staa T: Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age 1 75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J 2008; 156: 57-64.
22. Camm AJ, Evans KE, Ward DE, Martin A: The rhythm of the heart in active elderly subjects. Am Heart J 1980; 99: 598-603.
23. Lake FR, Cullen KJ, de Klerk NH, McCall MG, Rosman DL: Atrial fibrillation and mortality in an elderly population. Aust NZ J Med 1989; 19: 321-326.
24. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM: Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-241.
25. Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BHC, Stijnen T, Lip GYH, Witteman JCM: Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J 2006; 27: 949-953.
26. Chien K-L, Su T-C, Hsu H-C, Chang W-T, Chen P-C, Chen M-F, Lee Y-T: Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int J Cardiol 2010; 139: 173-180.
27. Bilato C, Corti M-C, Baggio G, Rampazzo D, Cutolo A, Iliceto S, Crepaldi G: Prevalence, functional impact, and mortality of atrial fibrillation in an older Italian population (from the Pro.V.A. study). Am J Cardiol 2009; 104: 1092-1097.
28. de Ruijter W, Westendorp RGJ, Macfarlane PW, Jukema JW, Assendelft WJJ, Gussekloo J: The routine electrocardiogram for cardiovascular risk stratification in old age: The Leiden 85-plus study. J Am Geriatric Soc 2007; 55: 872-877.
29. Bonhorst D, Mendes M, Adragao P, De Sousa J, Primo J, Leiria E, Rocha P: Prevalence of atrial fibrillation in the Portuguese population aged 40 and over: The FAMA study. Rev Port Cardiol 2010; 29: 331-350.
30. Murphy NF, Simpson CR, Jhund PS, Stewart S, Kirkpatrick M, Chalmers J, MacIntyre K, McMurray JJV: A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart 2007; 93: 606-612.
31. Schmutz M, Beer-Borst S, Meiltz A, Urban P, Gaspoz J-M, Costanza MC, Morabia A, Zimmermann M: Low prevalence of atrial fibrillation in asymptomatic adults in Geneva, Switzerland. Europace 2010; 12: 475-481.
32. Yap KB, Ng TP, Ong HY: Low prevalence of atrial fibrillation in community-dwelling Chinese aged 55 years or older in Singapore: A population-based study. J Electrocardiol 2008; 41: 94-98.
33. Iguchi Y, Kimura K, Aoki J, Kobayashi K, Terasawa Y, Sakai K, Shibazaki K: Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan: Analysis of 41,436 non-employee residents in Kurashiki-city. Circ J 2008; 72: 909-913.
34. Zhou Z, Hu D: An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J Epidemiol 2008; 18: 209-216.
35. Ruigomez A, Garcia Rodriguez LA, Johansson S, Wallander M-A, Edvardsson N: Risk of cerebrovascular accident after a first diagnosis of atrial fibrillation. Clin Cardiol 2007; 30: 624-628.
36. Onundarson PT, Thorgeirsson G, Jonmundsson E, Sigfusson N, Hardarson T: Chronic atrial fibrillation-epidemiologic features and 14 year follow-up: A case control study. Eur Heart J 1987; 8: 521-527.
37. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-988.
38. Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB: Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 2004; 94: 889-894.
39. Stewart S, Hart CL, Hole DJ, McMurray JJV: A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-364.
40. Simons L, Simons J, Friedlander Y, McCallum J: A comparison of risk factors for coronary heart disease and ischaemic stroke: The Dubbo study of Australian elderly. Heart Lung Circ 2009; 18: 330-333.
41. Bruggenjurgen B, Rossnagel K, Roll S, Andersson FL, Selim D, Muller-Nordhorn J, Nolte CH, Jungehulsing GJ, Villringer A, Willich SN: The impact of atrial fibrillation on the cost of stroke: The Berlin Acute Stroke Study. Value Health 2007; 10: 137-143.
42. Ghatnekar O, Glader E-L: The effect of atrial fibrillation on stroke-related inpatient costs in Sweden: A 3-year analysis of registry incidence data from 2001. Value Health 2008; 11: 862-868.
43. Meretoja A, Kaste M, Roine RO, Juntunen M, Linna M, Hillbom M, Marttila R, Erila T, Rissanen A, Sivenius J, Hakkinen U: Direct costs of patients with stroke can be continuously monitored on a national level: Performance, Effectiveness, and Costs of Treatment episodes in Stroke (PERFECT Stroke) Database in Finland. Stroke 2011; 42: 2007-2012.
44. United Nations: World Population Prospects: The 2006 Revision. New York, United Nations Department of Economic and Social Affairs, 2007.
45. Mai Y, Peng X, Chen W: How Fast is Population Ageing in China? Melbourne, Centre of Policy Studies, Monash University, 2009.
46. Kannel WB, Benjamin EJ: Status of the epidemiology of atrial fibrillation. Med Clin North Am 2008; 92: 17-40.
47. Friberg J, Scharling H, Gadsboll N, Jensen GB: Sex-specific increase in the prevalence of atrial fibrillation. Am J Cardiol 2003; 92: 1419-1423.
48. Frost L, Vestergaard P, Mosekilde L, Mortensen LS: Trends in incidence and mortality in the hospital diagnosis of atrial fibrillation or flutter in Denmark, 1980-1999. Int J Cardiol 2005; 103: 78-84.
49. Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D'Agostino RB: Secular trends in the prevalence of atrial fibrillation: The Framingham Study. Am Heart J 1996; 131: 790-795.
50. Tu HTH, Campbell BCV, Christensen S, Collins M, De Silva DA, Butcher KS, Parsons MW, Desmond PM, Barber PA, Levi CR, Bladin CF, Donnan GA, Davis SM; Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) Investigators: Pathophysiological determinants of worse stroke outcome in atrial fibrillation. Cerebrovasc Dis 2010; 30: 389-395.
51. Kannel WB, Wolf PA, Benjamin EJ, Levy D: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9N.
52. Lip G, Lim H: Atrial fibrillation and stroke prevention. Lancet Neurol 2007; 6: 981-993.
53. Yu H-C, Tsai Y-F, Chen M-C, Yeh C-H: Underuse of antithrombotic therapy caused high incidence of ischemic stroke in patients with atrial fibrillation. Int J Stroke 2012; 7: 112-117.
54. Baker WL, Cios DA, Sander SD, Coleman CI: Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009; 15: 244-252.
55. McBride D, Bruggenjurgen B, Roll S, Willich SN: Anticoagulation treatment for the reduction of stroke in atrial fibrillation: A cohort study to examine the gap between guidelines and routine medical practice. J Thromb Thrombolysis 2007; 24: 65-72.
56. PricewaterhouseCoopers: The Economic Cost of Atrial Fibrillation in Australia, 2010. Prepared for the National Stroke Foundation.
57. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP: Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154: 1-11.
58. Shah SV, Gage BF: Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011; 123: 2562-2570.
59. Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, Plumb JM: Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective. Thromb Haemost 2011; 105: 908-919.